The prevalence of heart failure is continuously growing despite the implementation of the four pillars of heart failure treatment: angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin II receptor blockers (ARBs), beta-blockers, aldosterone antagonists, and SGLT-II inhibitors [2]. This evidence concerns the gene ACE and heart failure.